Sinisa Savic on treatment outcomes in VEXAS syndrome
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Sinisa Savic on treatment outcomes in VEXAS syndrome
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research.
VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.
Read the full article:
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrhe
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv